Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.

Autor: Rausch J; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Dzama MM; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz., Dolgikh N; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Stiller HL; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Bohl SR; Department of Medical Oncology, Dana- Farber Cancer Institute, Boston, MA., Lahrmann C; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Kunz K; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Kessler L; Kura Oncology Inc., San Diego, CA 92130., Echchannaoui H; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Chen CW; Department of Systems Biology, Beckman Research Institute City of Hope, Duarte, CA., Kindler T; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Döhner K; Department of Internal Medicine III, Ulm University Hospital, Ulm., Burrows F; Kura Oncology Inc., San Diego, CA 92130., Theobald M; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Sasca D; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz., Kühn MWM; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz. mickuehn@uni-mainz.de.

Publikováno v: Haematologica [Haematologica] 2023 Oct 01; Vol. 108 (10), pp. 2837-2843. Date of Electronic Publication: 2023 Oct 01.

Selective elimination of immunosuppressive T cells in patients with multiple myeloma.

Autor: Awwad MHS; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Mahmoud A; Division of Applied Bioinformatics, German Cancer Research Center, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Bruns H; Department of Hematology and Oncology, Erlangen University Hospital, Erlangen, Germany., Echchannaoui H; Third Department of Medicine, University Cancer Center (UCT), University Medical Center (UMC) of the Johannes Gutenberg University, Erlangen, Germany.; German Cancer Consortium (Dktk), Partner Site Frankfurt/Mainz, Mainz, Germany., Kriegsmann K; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Lutz R; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Raab MS; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center and Department of Internal Medicine V, University of Heidelberg, 69120, Heidelberg, Germany., Bertsch U; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany., Munder M; Third Department of Medicine, University Cancer Center (UCT), University Medical Center (UMC) of the Johannes Gutenberg University, Erlangen, Germany., Jauch A; Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany., Weisel K; Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany., Maier B; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Weinhold N; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Salwender HJ; Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany., Eckstein V; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Fenk R; Department of Hematology, Oncology and Clinical Immunology, Düsseldorf University, Hamburg, Germany., Dürig J; Department of Hematology, Essen University, Hamburg, Germany., Brors B; Division of Applied Bioinformatics, German Cancer Research Center, Heidelberg, Germany.; National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Müller-Tidow C; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany.; Molecular Medicine Partnership Unit, Heidelberg University Hospital, EMBL, Heidelberg, Germany., Goldschmidt H; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany., Hundemer M; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany. michael.hundemer@med.uni-heidelberg.de.

Publikováno v: Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2602-2615. Date of Electronic Publication: 2021 Feb 17.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity.

Autor: Legscha KJ; Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany., Antunes Ferreira E; Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany., Chamoun A; Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany., Lang A; Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany., Awwad MHS; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Ton GNHQ; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Galetzka D; Department of Radiation Oncology and Radiotherapy, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany., Guezguez B; Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany.; German Cancer Consortium (DKTK), Partner Site, Mainz, Germany., Hundemer M; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Bourdon JC; School of Medicine, University of Dundee, Dundee, UK., Munder M; Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany.; Research Center for Immunotherapy (FZI), University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany., Theobald M; Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany.; German Cancer Consortium (DKTK), Partner Site, Mainz, Germany.; Research Center for Immunotherapy (FZI), University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany., Echchannaoui H; Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany echchann@uni-mainz.de.; German Cancer Consortium (DKTK), Partner Site, Mainz, Germany.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jun; Vol. 9 (6).

Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses.

Autor: Kim, Myung Sup¹ (AUTHOR), Kang, Hyeokgu¹ (AUTHOR), Baek, Jung-Hwan¹ (AUTHOR), Cho, Moon-Gyu¹ (AUTHOR), Chung, Eun Joo² (AUTHOR), Kim, Seok-Jun^3,4,5 (AUTHOR), Chung, Joon-Yong⁶ (AUTHOR), Chun, Kyung-Hee^1,7,8 (AUTHOR) khchun@yuhs.ac

Publikováno v: Experimental Hematology & Oncology. 12/19/2024, Vol. 13 Issue 1, p1-19. 19p.